REVIEW
|
doi:10.20944/preprints202306.1853.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
interleukin-1 beta (IL-1β); immune-checkpoint inhibitors (ICIs); non-small cell lung cancer (NSCLC); programmed death ligand 1 (PD-L1); therapeutic resistance
Online: 27 June 2023 (07:16:09 CEST)